Vesilut
Vesilute · VESILUT · Bladder Cytogen · Glu-Asp bladder peptide · Везилут
Vesilut (Vesilute) is the bladder cytogen on the official NPCRIZ list - the SKU Western research-chem menus most often omit. Chitomur is the bladder Cytomax. Pielotax is kidney. Sequence listings in English are messy; treat HPLC as the identity check.
Mechanism of Action
Urinary organs in class reviews. Almost no English RCT branded Vesilut. Honesty is the differentiator versus a fake “complete 41” blog that never listed this SKU.
Vesilut is the bladder cytogen - the pair Western catalogs often drop. Chitomur is the bladder Cytomax.
Source: NPCRIZ cytogen list (VESILUT - bladder); class reviews PMID: 15677927
Khavinson map
Canonical 41Used in bioregulator stacks
Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.
The Khavinson school
Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).
That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.
Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41
The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.
Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.
The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.
Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.
History of this molecule
This leaf exists because the 41 is incomplete without it. e-peptide: “VESILUT - bladder peptide.” US catalogs skip it, then people invent a kidney cytogen that is not on the poster.
Glu-Asp (ED) shows up in some tables; other tables are silent. We list ED as catalog-common and flag the dispute. We do not invent a tetrapeptide to look complete.
Chitomur is the complex. Vesugen is vessels (KED) - another V-name trap.
Caveats
A defined sequence is not an FDA indication. Bladder cytogens sit in a Russian experimental-gerontology literature with limited Western replication. “Oral bioavailability because PEPT1” is real peptide-transport biology; it is not proof this SKU treats the organ disease. Gray-market identity is a live problem - HPLC is the only way to know the vial is the sequence on the label. Name collision with Vesugen (vessels) is how wrong vials get shipped.
Full 41-map: Khavinson bioregulators index · Bioregulator stacks
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Khavinson-style cytogen course | 1–2 capsules/day or 1–2 mg SC | Daily for 10 days, 1-2x per year | Manufacturer capsules vs research vials are different presentations. Not an OAB drug. |
Administration
Expected Timeline
Who Is It For?
Bladder tissue (research)
LowCytogen pair to Chitomur. Not mirabegron. Not a kidney peptide.
Reconstitution Example
Safety & Considerations
Research peptide / Cytomed cytogen. Not FDA-approved. Sequence identity on gray-market vials is unverified without HPLC. Do not confuse with Vesugen.
Regulatory & Legal Status
Bladder cytogen (Vesilut). Distinct from Chitomur (extract) and Vesugen (KED vessels). Not an OAB drug
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Frequently Asked Questions
Vesilut vs Vesugen vs Chitomur vs Pielotax?▼
Why is this missing on other sites?▼
Sequence?▼
OAB drug?▼
References
- Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
- Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2013). PMID: 23888677
- Khavinson VKh, Morozov VG “Peptide regulation of aging: from experimental studies to clinical practice.” Advances in Gerontology (2003). PMID: 14523363
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code